Company news

Citius Pharmaceuticals, Inc. news in 2021

Citius Pharmaceuticals, Inc.'s news releases, calls and decks from 2021, newest first.

View company

Citius Pharmaceuticals, Inc. Reports Fiscal Full Year 2021 Financial Results and Provides Business Update

December 14, 2021

Citius Pharmaceuticals Completes Enrollment in the Pivotal Phase 3 Study of its Cancer Immunotherapy I/ONTAK for the Treatment of Cutaneous T-Cell Lymphoma

December 5, 2021

Citius Pharmaceuticals Expands Management Team with Appointment of Kelly Creighton, PhD as Executive Vice President of Chemistry, Manufacturing and Controls

November 4, 2021

Citius Pharmaceuticals Acquires Dr. Reddy's Laboratories' License for Late-Phase 3 Oncology Immunotherapy (E7777) for the Treatment of Cutaneous T-Cell Lymphoma and other Cancer Indications

September 6, 2021

Citius Pharmaceuticals, Inc. Reports Third Fiscal Quarter 2021 Financial Results and Provides General Business Update

August 11, 2021

Citius Pharmaceuticals, Inc. Provides First Half 2021 Business Update, Highlights Upcoming Milestones

July 6, 2021

Citius Pharmaceuticals, Inc. Announces Positive Recommendation by Independent Data Monitoring Committee to Continue the Mino-Lok® Phase 3 Trial as Planned

June 30, 2021

Citius Pharmaceuticals Expands Scientific Advisory Board with Addition of Dr. John Laffey, Expert in Stem Cell and Gene Therapies for ARDS

June 14, 2021

Citius Pharmaceuticals Achieves Next Interim Analysis Milestone in its Mino-Lok® Phase 3 Trial

June 7, 2021

Citius Pharmaceuticals to be Added to Russell 2000® Index

June 6, 2021

Citius Pharmaceuticals Selected to Receive Best Poster Award at the International Society for Cell and Gene Therapy 2021 Annual Meeting

May 24, 2021

Citius Pharmaceuticals, Inc. Announces Appointment of Ilanit Allen as Vice President, Corporate Communications and Investor Relations

May 16, 2021

Citius Pharmaceuticals, Inc. Reports Second Fiscal Quarter 2021 Financial Results and Provides General Business Update

May 12, 2021

Citius Pharmaceuticals Announces $76.5 Million Registered Direct Offering Priced At-the-Market under Nasdaq Rules

February 16, 2021

Citius Pharmaceuticals Announces Closing of $20.0 Million Private Placement Offering Priced At-the-Market

January 26, 2021

Citius Pharmaceuticals Announces $20.0 Million Private Placement Priced At-the-Market

January 24, 2021

Decks in 2021